Evidence map›Paper›PMID 27981572›Full record

GuidelineClinical pharmacology and therapeutics2017

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

B Moriyama, A Owusu Obeng, J Barbarino, S R Penzak, S A Henning, S A Scott, Jag Agúndez, J R Wingard, H L McLeod, T E Klein and 3 more

Erratum issuedAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 205 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Frontiers in pharmacology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pre-emptiveFrontiers in pharmacology · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

B MoriyamaNational Institutes of Health Clinical Center Pharmacy Department, Bethesda, Maryland, USA.
A Owusu ObengThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
J BarbarinoDepartment of Genetics, Stanford University, Stanford, California, USA.
S R PenzakDepartment of Pharmacotherapy, University of North Texas, System College of Pharmacy, Fort Worth, Texas, USA.
S A HenningNational Institutes of Health Clinical Center Pharmacy Department, Bethesda, Maryland, USA.
S A ScottThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jag AgúndezDepartment of Pharmacology, University of Extremadura, Cáceres, Spain.
J R WingardUniversity of Florida College of Medicine, Gainesville, Florida, USA.
H L McLeodDeBartolo Family Personalized Medicine Institute, Division of Population Sciences, Moffitt Cancer Center, Tampa, Florida, USA.
T E KleinDepartment of Genetics, Stanford University, Stanford, California, USA.
S J CrossDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
K E CaudleDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
T J WalshTransplantation-Oncology Infectious Diseases Program, Departments of Medicine, Pediatrics, and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, New York, USA.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
THE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2009
$24.0M
Biorepository for Genomic Medicine in diverse CommunitiesU01HG006380 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BOTTINGER, ERWIN P. · 2011 to 2015
$4.5M
Clinical Pharmacogenetics Implementation Consortium (CPIC)R24GM115264 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KLEIN, TERI ELLEN, RELLING, MARY V · 2015 to 2017
$3.6M
The Pharmacogenomic Control of Clopidogrel Response in Acute Coronary SyndromesK23GM104401 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT, STUART ALEXANDER · 2013 to 2016
$778k
NCI NIH HHS P30 CA076292NHGRI NIH HHS U01 HG006380NIGMS NIH HHS K23 GM104401NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM115264NIGMS NIH HHS U01 GM061374
6 · The paper itself

Abstract

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

Indexed as

Drug-Related Side Effects and Adverse ReactionsVoriconazoleAntifungal AgentsCytochrome P-450 CYP2C19Dose-Response Relationship, DrugGenotyping TechniquesHumansMetabolic Clearance RatePatient SelectionPharmacogenomic VariantsRisk AssessmentAntifungal AgentsCYP2C19 protein, humanCytochrome P-450 CYP2C19Voriconazole

Identifiers

PMID27981572
PMCPMC5474211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.